Microviable Therapeutics announces Research Collaboration with Venter Pharma and Inmunomet Intolerancia y Disbiosis

2022-07-08T13:12:03+02:008 de July de 2022|

Gijón, July 7, 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, today announced that it has entered into a research contract with Venter Pharma SL. and Inmunomet [...]